Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone
15.6.2026 06:05:00 CEST | Business Wire | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/

Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk.
Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making.
“Black Recon represents a major step forward in integrated reconnaissance for ground forces,” said Dr. JihFen Lei, President of Teledyne Defense and Aerospace Group and Senior Vice President of Teledyne Technologies. “By bringing autonomous launch, recovery, and recharging directly to the vehicle, we give operators persistent situational awareness, faster access to actionable intelligence, and greater protection in high-tempo missions.”
Key system capabilities include:
- Autonomous launch, recovery, and recharge from the safety of the platform
- Three-UAV rotation for near-continuous overwatch
- Thermal and visible payloads for real-time imagery and targeting data
- Global Navigation Satellite System (GNSS)-denied operation enabled by advanced sensors and visual navigation
- Radio-silent missions using Visual Inertial Navigation, without reliance on RF links
- Extended range and radio coverage through onboard relay capability
- Compatible operation with Black Hornet 4 nano-drone
- Optional 100-gram mission modules for future lethality, sensor, and CBRN payloads
A Fully Integrated, Autonomous Reconnaissance Capability
Black Recon is a compact, hardened system for vehicles or fixed installations that deploys up to three micro-UAVs in rotation for persistent surveillance. Each UAV launches autonomously, performs reconnaissance, surveillance, and target acquisition (RSTA) missions, then returns to the launcher for capture, docking, and recharging. The result is uninterrupted ISR coverage day or night while keeping personnel protected inside the platform.
Designed for ‘Dynamic Reusability’ in High-Tempo Operations
Unlike legacy drones adapted for dismounted use, Black Recon is engineered for mounted platforms, enabling immediate ISR deployment without external aviation support.
With 50- to 60-minute flight times and speeds up to 25 m/s per UAV, Black Recon extends surveillance beyond traditional engagement ranges, supporting continuous target tracking, rapid threat detection, and shortening the decision cycle across all mission profiles.
Low SWaP, High Performance
Weighing less than 450 grams, each Black Recon UAV combines low size, weight, and power with advanced sensing derived from Teledyne FLIR Defense’s proven nano-UAS portfolio. Autonomous navigation allows missions to continue in GPS-jammed or spoofed environments.
Expanding Beyond the Battlefield
Originally developed for military use, Black Recon’s flexible architecture also supports public safety and security applications, including:
- Remote first responder deployments for law enforcement
- Border and perimeter security
- Critical infrastructure monitoring
- Maritime and riverine patrols
Its rugged, network-enabled design supports both fixed and mobile deployment, providing rapid situational awareness in remote and hard-to-reach environments.
Future-Ready, Modular by Design
Black Recon’s open mission-module architecture is built to evolve with operational requirements. Planned future modules include lethality payloads and CBRN detection sensors, expanding the system from persistent reconnaissance to hazard detection and active engagement.
Black Recon is available for order now, with deliveries expected to begin in 2027.
Visit Teledyne FLIR Defense at Eurosatory, Hall 5A, Stand A129, to see the Black Recon in person or learn more online.
About Teledyne FLIR Defense
Teledyne FLIR Defense has been providing advanced, mission-critical technology and systems for more than 45 years. Our products are on the frontlines of the world’s most pressing military, security and public safety challenges. As a global leader in thermal imaging, we design and build sophisticated surveillance sensors for air, land and maritime use. We develop the most rugged, trusted unmanned air and ground platforms, as well as intelligent sensing devices used to detect chemicals, biological agents, radiation and explosives. At Teledyne FLIR Defense we bring together this expertise to deliver solutions that enable critical decisions and keep our world safe – from any threat, anywhere. To learn more, visit us online or follow @flir_defense.
About Teledyne Technologies
Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260614388428/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom